RxDoctor Payments Data

Vishal Patel, MD

Interventional Cardiology · Santa Rosa, CANPI 1144455825

Payments from drug & device makers

$71,654in general payments, 2019–2025

Across 401 payments — averaging $178.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$57K
  • Edwards Lifesciences$6K
  • Abbott$5K
  • Boston Scientific$448
  • Novartis$266
  • Abiomed$259
  • plus $3K from 32 others
$2,600in research payments, 2019–2025

Across 1 payment — averaging $2600.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$3K

What the payments were for

  • Consulting fees$5251%
  • Speaking & faculty fees$51,58372%
  • Travel & lodging$6,0378%
  • Food & beverage$13,50919%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$71,654 in reported general payments places this provider in the 80th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$525,586
Medicare patients
891
Services billed
3,437

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis19$585,132
EliquisApixaban432$580,223
JardianceEmpagliflozin192$257,089
EntrestoSacubitril/Valsartan177$252,146
Repatha SureclickEvolocumab103$111,105
XareltoRivaroxaban49$61,923
Praluent PenAlirocumab32$33,630
Repatha SyringeEvolocumab25$27,677
OzempicSemaglutide16$15,116
NexlizetBempedoic Acid/Ezetimibe18$10,908
Ezetimibe246$10,074
Atorvastatin Calcium712$8,881
Valsartan234$7,488
BrilintaTicagrelor12$6,902
Rosuvastatin Calcium248$5,879

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$178$1,165,355451 claims
Boehringer IngelheimJardiance$165$257,089192 claims
NovartisEntresto$266$252,146177 claims
Johnson & JohnsonXarelto$88$61,92349 claims
Esperion Therapeutics, Inc.Nexlizet$98$10,90818 claims
AstraZenecaBrilinta$95$6,90212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in Santa Rosa

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →